Αρχική World News Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously... World News Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Από Ogkologos - 30 Απριλίου, 2026 260 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Pembrolizumab Combinations Show Promise in mCRPC 21 Νοεμβρίου, 2020 Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney 10 Ιανουαρίου, 2022 Cancer in Lymph Nodes May Help Tumors Spread by Enlisting Immune... 27 Μαΐου, 2022 For Common Form of Bladder Cancer, Chemo Combo Effective Alternative to... 29 Αυγούστου, 2022 Φόρτωση περισσοτέρων HOT NEWS Removing senescent immune cells could be the key to preventing some... Ifosfamide May Be Treatment of Choice for Some People with Ewing... Woman Battles Breast Cancer While Pregnant, Delivers Healthy Baby Boy A Propensity Score Matched Study Supports the Use of Allogeneic HSCT...